Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival

Cancer

Volumn 120, Issue 11, 2014, Pages 1677-1685

  Cohen, Jonathon B ^a   Geyer, Susan M ^a   Lozanski, Gerard ^a   Zhao, Weiqiang ^a   Heerema, Nyla A ^a   Hall, Nathan C ^b   Nagar, Veena A ^b   Hemminger, Jessica A ^a   Jones, Jeffrey A ^a   Porcu, Pierluigi ^a   Christian, Beth A ^a   Baiocchi, Robert A ^a   Maddocks, Kami J ^a   Flynn, Joseph M ^a   Devine, Steven M ^a   Blum, Kristie A ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

B cell lymphoma; C myc genes; immunoglobulin heavy chain genes; non Hodgkin lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; MYC PROTEIN; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; INDUCTION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

B-CELL LYMPHOMA; C-MYC GENES; IMMUNOGLOBULIN HEAVY CHAIN GENES; NON-HODGKIN LYMPHOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; GENES, BCL-2; HUMANS; INDUCTION CHEMOTHERAPY; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDNISONE; PROTO-ONCOGENE PROTEINS C-MYC; TOMOGRAPHY, X-RAY COMPUTED; VINCRISTINE;

EID: 84901318824     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28642     Document Type: Article

References (20)

1. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009; 114: 3533-3537.
2. Cuccuini W, Briere J, Mounier N, et al. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood. 2012; 119: 4619-4624.
3. Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012; 30: 3452-3459.
4. Horn H, Ziepert M, Becher C, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013; 121: 2253-2263.
5. Snuderl M, Kolman OK, Chen YB, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol. 2010; 34: 327-340.
6. Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009; 114: 2273-2279.
7. Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012; 30: 3460-3467.
8. Abramson JS, Barnes JA, Feng Y, et al. Double hit lymphomas: evaluation of prognostic factors and impact of therapy [abstract]. Blood (ASH Annual Meeting Abstracts). 2012; 120. Abstract 1619.
9. Dunleavy K, Pittaluga S, Wayne AS,. MYC+ aggressive-B-cell lymphomas: novel therapy of untreated Burkitt lymphoma (BL) and MYC+ diffuse large B-cell lymphoma (DLBCL) with DA-EPOCH-R [abstract]. Ann Oncol. 2011; 22 (suppl 4): 106. Abstract 071.
10. Jaglal MV, Peker D, Tao JG, Cultrera JL,. Double and triple hit diffuse large B cell lymphomas and first line therapy [abstract]. Blood (ASH Annual Meeting Abstracts). 2012; 120. Abstract 4885.
11. Meignan M, Gallamini A, Haioun C, Polliack A,. Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010. Leuk Lymphoma. 2010; 51: 2171-2180.
12. Fleiss JL, Levin BA, Paik MC,. Statistical Methods for Rates and Proportions. 3rd ed. Hoboken, NJ: Wiley-Interscience; 2003.
13. Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010; 28: 3360-3365.
14. Kojima M, Nishikii H, Takizawa J, et al. MYC rearrangements are useful for predicting outcomes following rituximab and chemotherapy: multicenter analysis of Japanese patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2013; 54: 2149-2154.
15. Akyurek N, Uner A, Benekli M, Barista I,. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer. 2012; 118: 4173-4183.
16. Lin P, Dickason TJ, Fayad LE, et al. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Cancer. 2012; 118: 1566-1573.
17. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007; 25: 571-578.
18. Cashen AF, Dehdashti F, Luo J, Homb A, Siegel BA, Bartlett NL,. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med. 2011; 52: 386-392.
19. Pregno P, Chiappella A, Bello M, et al. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood. 2012; 119: 2066-2073.
20. Pedersen MO, Gang AO, Poulsen TS, et al. MYC translocation partner determines survival in double-hit BCL2/MYC lymphoma. APMIS. 2012; 120: 6-7.